Accelerate biologics innovation from target to candidate
ChemPartner’s integrated platform for monoclonal, bispecific, and ADC/XDC programs combines protein science, stable cell line development, antibody discovery, engineering, structural biology, and conjugation support in one coordinated workflow — backed by 2,000+ scientists across a global network.
Integrated antibody discovery, from target to candidate
ChemPartner provides end-to-end biologics discovery services designed to move programs from target and reagent generation through lead identification, optimization, and candidate selection.
Integrated workflows span protein science, assay development, antibody discovery, lead optimization, structural biology, and developability assessment in one coordinated CRO environment — with the option to transition into downstream development, GMP manufacturing, and regulatory support.
Monoclonal
antibodies
Discover and optimize high-quality monoclonal antibodies with the affinity, specificity, and developability needed to advance.
Bispecific
antibodies
Design and engineer multispecific molecules that engage complementary targets to address complex disease biology.
Antibody-drug conjugates (ADCs)
Integrate antibody discovery with linker-payload strategy and conjugation expertise to develop differentiated ADC candidates.
XDC & multispecific conjugates
Build next-generation conjugates that combine targeted delivery with tailored payload, linker, and multispecific formats.
TCR-mimic antibodies
Generate TCR-mimic antibodies that recognize intracellular-derived peptide targets presented on the cell surface.
Engineered fragments & next-gen biologics
Create optimized antibody fragments and novel biologic formats to meet challenging target, tissue-penetration, and delivery needs.
Proven biologics discovery at global scale
ChemPartner brings deep experience spanning preclinical through marketed biologics — across oncology, immunology, neuroscience, cardiovascular, and metabolic disease areas.
The organization’s broader biologics infrastructure — spanning Shanghai (China), Boston (US), and Kent (UK) — supports continuity from discovery through development and manufacturing.
SCIENTISTS & PROFESSIONALS
ANTIBODY DISCOVERY PROGRAMS
DRUGS TO FDA APPROVAL
GLOBAL DISCOVERY SITES
Why teams choose ChemPartner for biologics discovery
Integrated workflow, no fragmented handoffs
Reagent generation through lead ID, optimization, candidate selection, and downstream CMC transition — in one coordinated organization that reduces technology-transfer delays and operational complexity.
Flexible platform selection
Multiple platforms — hybridoma, phage display, yeast display, and Beacon single B-cell cloning — matched to target biology, developability, immunization strategy, and modality.
Built for challenging targets
Difficult membrane and GPCR targets, ion channels, bispecific and ADC/XDC workflows, TCR-mimic programs, rapid lead generation, and downstream CMC continuity.
Optimization built into the workflow
Humanization, affinity maturation, multispecific engineering, epitope mapping, developability assessment, and AI-enabled structure-guided optimization — wet-lab plus computational.
Global discovery infrastructure
A network across Shanghai, Boston, Copenhagen, and Kent supporting close collaboration, scalable execution, and efficient downstream transition.
Well-suited for complex programs
Difficult membrane and GPCR targets, ion channels, bispecific and ADC/XDC workflows, TCR-mimic programs, rapid lead generation, and downstream CMC continuity.
Core biologics discovery capabilities
Six integrated platforms span the full discovery workflow — from reagent generation and antibody discovery to engineering, structural biology, and conjugate development.
Typical biologics discovery timeline
Representative workflows — actual timelines vary with target complexity, platform selection, screening strategy, and downstream requirements.
Reagent generation
Assay development
Lead generation
Lead optimization
Candidate selection & CMC
Beacon ~3–5 mo · hybridoma / phage / yeast ~6–8 mo
Therapeutic areas supported
ChemPartner supports:
ChemPartner supports biologics discovery programs across a broad range of therapeutic areas.
One integrated path, from DNA to IND/BLA
ChemPartner’s broader biologics platform extends beyond discovery into development and manufacturing — reducing transition risk between discovery and downstream CMC workflows.
Frequently asked questions
What biologics discovery services does ChemPartner provide?
ChemPartner provides integrated biologics discovery services spanning protein science, assay development, antibody discovery, antibody engineering, structural biology, developability assessment, and ADC/XDC discovery support.
What antibody discovery platforms does ChemPartner support?
ChemPartner supports hybridoma, phage display, yeast display, and Beacon™ single B-cell cloning workflows, along with antibody humanization, affinity maturation, and multispecific engineering capabilities.
Can ChemPartner support bispecific antibodies and ADC programs?
Yes. ChemPartner supports bispecific antibody engineering and integrated ADC/XDC discovery workflows, including linker-payload chemistry, conjugation development, and characterization support.
Can ChemPartner support difficult membrane protein targets?
Yes. ChemPartner highlights experience supporting membrane proteins, GPCR-related targets, ion channels, multi-transmembrane proteins, and TCR-mimic antibody discovery programs.
What biophysical characterization methods are available?
ChemPartner supports affinity and interaction analysis using Cytiva Biacore™, Sartorius Octet, and Carterra systems for kinetics, Fc receptor binding, and epitope binning workflows.
Does ChemPartner provide downstream biologics development support?
Yes. ChemPartner’s broader platform extends from early discovery through biologics development, process development, GMP manufacturing, and regulatory support.
What is the typical biologics discovery timeline?
Representative workflows may include approximately 3–5 months for Beacon™-based lead generation or 6–8 months for hybridoma, phage display, or yeast display programs, depending on target complexity and screening strategy.
Advance complex biologics programs with an integrated discovery partner
Accelerate antibody discovery and candidate optimization with flexible platform technologies, integrated protein science and characterization, and a streamlined path into downstream biologics development and manufacturing.
